文献速递白血病

BAALC表达在高危急性早幼粒细胞白血病中的临床影响

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.
PubMed 文献 · Blood Adv · 2017-09-15

研究采用实时逆转录聚合酶链反应检测BAALC表达,发现急性早幼粒细胞白血病(APL)患者BAALC表达显著低于其他亚型急性髓系白血病(P < .001)。在221例接受全反式维甲酸联合蒽环类化疗的新诊断APL患者中,BAALC过表达与较短无病生存期(DFS)相关(HR 4.43;95%CI 1.29-15.2;P = .018),且在高危患者中独立相关(HR 5.3;95%CI 1.14-24.5;P = .033)。作者认为BAALC表达可能有助于细化APL风险分层,但需在独立队列中验证。

要点

  • APL患者BAALC表达显著低于其他AML亚型(P < .001)。
  • BAALC过表达与较短DFS相关(HR 4.43;95%CI 1.29-15.2;P = .018)。
  • 高危APL患者中BAALC过表达独立关联较短DFS(HR 5.3;95%CI 1.14-24.5;P = .033)。

核心结论

  • BAALC表达可能有助于细化APL风险分层,但需在独立队列中验证。

研究设计与样本

  • 采用实时逆转录聚合酶链反应检测BAALC表达,纳入221例连续新诊断APL患者(中位年龄35岁;范围18-82岁),均接受全反式维甲酸联合蒽环类化疗。

主要发现

  • APL患者BAALC表达显著低于其他AML亚型(P < .001)。
  • BAALC过表达与较短DFS相关(HR 4.43;95%CI 1.29-15.2;P = .018)。
  • Cox比例风险模型显示,BAALC过表达在总队列中独立关联较短DFS(HR 5.26;95%CI 1.52-18.2;P = .009)。
  • 高危患者(初始白细胞计数 >10 × 10^9/L)中BAALC过表达独立关联较短DFS(HR 5.3;95%CI 1.14-24.5;P = .033)。

临床怎么用

  • 作者认为BAALC表达可能有助于细化APL风险分层,但需在独立队列中验证。

局限性

  • BAALC表达用于细化APL风险分层的结论需在独立队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although overexpression of the brain and acute leukemia, cytoplasmic (BAALC) gene is associated with primary resistant disease and shorter relapse-free, disease-free, and overall survival in different subsets of acute myeloid leukemia (AML), little is known about its clinical impact in acute promyelocytic leukemia (APL). Using real-time reverse transcriptase polymerase chain reaction, we showed that BAALC expression is significantly lower in APL compared with other subsets of AML (P < .001). We also demonstrated that BAALC overexpression was associated with shorter disease-free survival (DFS) (hazard ratio [HR], 4.43; 95% confidence interval [CI], 1.29-15.2; P = .018) in 221 consecutive patients (median age, 35 years; range, 18-82 years) with newly diagnosed APL homogeneously treated with all-trans retinoic acid and anthracycline-based chemotherapy. Cox proportional hazard modeling showed that BAALC overexpression was independently associated with shorter DFS in the total cohort (HR, 5.26; 95% CI, 1.52-18.2; P = .009) and in patients with high-risk disease (ie, those with initial leukocyte counts >10 × 109/L) (HR, 5.3; 95% CI, 1.14-24.5; P = .033). We conclude that BAALC expression could be useful for refining risk stratification in APL, although this needs to be confirmed in independent cohorts.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lucena-Araujo AR, Pereira-Martins DA, Koury LC, et al. Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. Blood Adv. 2017. PMID: 29296827. doi:10.1182/bloodadvances.2017005926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。